{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T09:45:28Z","timestamp":1780479928240,"version":"3.54.1"},"reference-count":28,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2010,10,1]],"date-time":"2010-10-01T00:00:00Z","timestamp":1285891200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2010,10]]},"DOI":"10.1016\/j.clinthera.2010.10.006","type":"journal-article","created":{"date-parts":[[2010,11,22]],"date-time":"2010-11-22T04:11:28Z","timestamp":1290399088000},"page":"1871-1888","source":"Crossref","is-referenced-by-count":56,"title":["A meta-analysis of the efficacy and tolerability of interferon-\u03b2 in multiple sclerosis, overall and by drug and disease type"],"prefix":"10.1016","volume":"32","author":[{"given":"Shekoufeh","family":"Nikfar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roja","family":"Rahimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Abdollahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2010.10.006_bib1","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1002\/msj.20030","article-title":"Neurotherapeutics in multiple sclerosis: Novel agents and emerging treatment strategies","volume":"75","author":"DeAngelis","year":"2008","journal-title":"Mt Sinai J Med."},{"key":"10.1016\/j.clinthera.2010.10.006_bib2","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/j.1600-0404.2008.01026.x","article-title":"Diagnosis and treatment of multiple sclerosis","volume":"188","author":"Myhr","year":"2008","journal-title":"Acta Neurol Scand Suppl."},{"key":"10.1016\/j.clinthera.2010.10.006_bib3","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1212\/01.wnl.0000316802.35974.34","article-title":"Temporal trends in the incidence of multiple sclerosis: A systematic review","volume":"71","author":"Alonso","year":"2008","journal-title":"Neurology."},{"key":"10.1016\/j.clinthera.2010.10.006_bib4","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.clineuro.2010.03.010","article-title":"Therapy of MS","volume":"112","author":"Vosoughi","year":"2010","journal-title":"Clin Neurol Neurosurg."},{"key":"10.1016\/j.clinthera.2010.10.006_bib5","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1191\/1352458503ms932oa","article-title":"Effects of glatiramer acetate on relapse rate and accumulated disability in multiple sclerosis: Meta-analysis of three double-blind, randomized, placebo-controlled clinical trials","volume":"9","author":"Martinelli Boneschi","year":"2003","journal-title":"Mult Scler."},{"key":"10.1016\/j.clinthera.2010.10.006_bib6","doi-asserted-by":"crossref","first-page":"236","DOI":"10.5114\/aoms.2010.13901","article-title":"A meta-analysis on the efficacy and tolerability of natalizumab in relapsing multiple sclerosis","volume":"6","author":"Nikfar","year":"2010","journal-title":"Arch Med Sci."},{"issue":"4","key":"10.1016\/j.clinthera.2010.10.006_bib7","first-page":"CD002127","article-title":"Mitoxantrone for multiple sclerosis","author":"Martinelli Boneschi","year":"2005","journal-title":"Cochrane Database Syst Rev."},{"key":"10.1016\/j.clinthera.2010.10.006_bib8","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1038\/nrd2422","article-title":"Interferons at age 50: Past, current and future impact on biomedicine","volume":"6","author":"Borden","year":"2007","journal-title":"Nat Rev Drug Discov."},{"key":"10.1016\/j.clinthera.2010.10.006_bib9","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1016\/0002-9378(95)90402-6","article-title":"Interferons: Biochemistry and mechanisms of action","volume":"172","author":"Tyring","year":"1995","journal-title":"AmJ Obstet Gynecol."},{"key":"10.1016\/j.clinthera.2010.10.006_bib10","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.jbspin.2009.03.012","article-title":"Interferons and autoimmune disorders","volume":"76","author":"Meyer","year":"2009","journal-title":"Joint Bone Spine."},{"key":"10.1016\/j.clinthera.2010.10.006_bib11","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1212\/01.WNL.0000146958.77317.3E","article-title":"Interferon beta-1b in secondary progressive MS: Results from a 3-year controlled study","volume":"63","author":"Panitch","year":"2004","journal-title":"Neurology."},{"key":"10.1016\/j.clinthera.2010.10.006_bib12","first-page":"1498","article-title":"Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing\/remitting multiple sclerosis[published correction appears in Lancet. 1999;353:678]","volume":"352","year":"1998","journal-title":"Lancet."},{"key":"10.1016\/j.clinthera.2010.10.006_bib13","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1212\/WNL.43.4.655","article-title":"Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, doubleblind, placebo-controlled trial","volume":"43","year":"1993","journal-title":"Neurology."},{"key":"10.1016\/j.clinthera.2010.10.006_bib14","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1136\/jnnp.2003.010090","article-title":"Multicentre, randomised, double blind, placebo controlled, phase III study of weekly, low dose, subcutaneous interferon beta-1a in secondary progressive multiple sclerosis","volume":"75","author":"Andersen","year":"2004","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"10.1016\/j.clinthera.2010.10.006_bib15","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1016\/S0140-6736(98)10039-9","article-title":"Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis","volume":"352","year":"1998","journal-title":"Lancet."},{"key":"10.1016\/j.clinthera.2010.10.006_bib16","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.jneuroim.2009.04.015","article-title":"Recombinant interferon-beta therapy and neuromuscular disorders","volume":"212","author":"St\u00fcbgen","year":"2009","journal-title":"J Neuroimmunol."},{"key":"10.1016\/j.clinthera.2010.10.006_bib17","series-title":"Randomised Controlled Trials","author":"Jadad","year":"1998"},{"key":"10.1016\/j.clinthera.2010.10.006_bib18","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/j.1600-0404.1999.tb00397.x","article-title":"Natural interferon-beta treatment of relapsing-remitting and secondary-progressive multiple sclerosis patients. A two-year study","volume":"100","author":"Patti","year":"1999","journal-title":"Acta Neurol Scand."},{"key":"10.1016\/j.clinthera.2010.10.006_bib19","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1212\/WNL.56.11.1496","article-title":"Randomized controlled trial of interferon-beta-1a in secondary progressive MS: Clinical results","volume":"56","year":"2001","journal-title":"Neurology."},{"key":"10.1016\/j.clinthera.2010.10.006_bib20","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1212\/WNL.60.1.44","article-title":"Interferon beta-1a in primary progressive MS: An exploratory, randomized, controlled trial","volume":"60","author":"Leary","year":"2003","journal-title":"Neurology."},{"key":"10.1016\/j.clinthera.2010.10.006_bib21","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/ana.410390304","article-title":"Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis [published correction appears in Ann Neurol. 1996; 40:480]","volume":"39","author":"Jacobs","year":"1996","journal-title":"Ann Neurol."},{"key":"10.1016\/j.clinthera.2010.10.006_bib22","first-page":"1484","article-title":"A meta-analysis of interferon-beta in the secondary progressive multiple sclerosis [in Chinese]","volume":"89","author":"Fan","year":"2009","journal-title":"Zhonghua Yi Xue Za Zhi."},{"key":"10.1016\/j.clinthera.2010.10.006_bib23","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1212\/WNL.46.4.907","article-title":"Defining the clinical course of multiple sclerosis: Results of an international survey","volume":"46","author":"Lublin","year":"1996","journal-title":"Neurology."},{"key":"10.1016\/j.clinthera.2010.10.006_bib24","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S0140-6736(02)08430-1","article-title":"Every-other-day interferon beta-1b vs once-weekly interferon beta-1a for multiple sclerosis: Results of a 2-year prospective randomised multicentre study (INCOMIN)","volume":"359","author":"Durelli","year":"2002","journal-title":"Lancet."},{"key":"10.1016\/j.clinthera.2010.10.006_bib25","doi-asserted-by":"crossref","first-page":"638","DOI":"10.3923\/ijp.2010.638.644","article-title":"A systematic review on the efficacy of interferon beta in relapsing remitting multiple sclerosis; comparison of different formulations","volume":"6","author":"Nikfar","year":"2010","journal-title":"Int J Pharmacol."},{"key":"10.1016\/j.clinthera.2010.10.006_bib26","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S0140-6736(03)12512-3","article-title":"Interferons in relapsing remitting multiple sclerosis: A systematic review","volume":"361","author":"Filippini","year":"2003","journal-title":"Lancet."},{"key":"10.1016\/j.clinthera.2010.10.006_bib27","first-page":"546","article-title":"In vivo myelosuppression by combination interferon treatment: Antagonism of MuIFN-gamma and MuIFN- beta myelosuppressive effects","volume":"6","author":"Naldini","year":"1987","journal-title":"J Biol Response Mod."},{"key":"10.1016\/j.clinthera.2010.10.006_bib28","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1007\/s00415-004-0619-5","article-title":"Hepatic injury, liver monitoring and the betainterferons for multiple sclerosis","volume":"251","author":"Tremlett","year":"2004","journal-title":"J Neurol."}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291810003450?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291810003450?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,6]],"date-time":"2018-12-06T12:51:28Z","timestamp":1544100688000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291810003450"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,10]]},"references-count":28,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2010,10]]}},"alternative-id":["S0149291810003450"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2010.10.006","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2010,10]]}}}